NCT03858153 is a Phase 2 clinical trial of EXCAP Exercise in Neuropathy;Peripheral, sponsored by University of Rochester.

Who is sponsoring NCT03858153?

NCT03858153 is sponsored by University of Rochester.

What drugs are being tested in NCT03858153?

Interventions in NCT03858153: EXCAP Exercise, Nutrition Education.

What condition does NCT03858153 study?

NCT03858153 studies Neuropathy;Peripheral.

Is NCT03858153 still recruiting?

NCT03858153 is currently completed. Last updated 22 December 2025.

Last reviewed 2025-12-22 · How we verify

NCT03858153

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Exercise and Nutrition Interventions During Chemotherapy K07

Completed Phase 2 Last updated 22 December 2025

What this trial tests

Phase 2 trial testing EXCAP Exercise in Neuropathy;Peripheral in 80 participants. Completed in 27 August 2025.

Timeline

15 April 2019

Primary endpoint
27 August 2025

27 August 2025

Quick facts

Lead sponsor	University of Rochester
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	supportive care
Enrollment	80
Start date	15 April 2019
Primary completion	27 August 2025
Estimated completion	27 August 2025
Sites	2 locations across United States

Drugs / interventions tested

EXCAP Exercise
Nutrition Education

Conditions studied

Neuropathy;Peripheral — all drugs for Neuropathy;Peripheral →

Sponsor

University of Rochester

Who can join

18 and older, female only, with Neuropathy;Peripheral. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Chemotherapy-induced peripheral neuropathy (CIPN) is a highly prevalent and severe side-effect of taxane chemotherapy, often used to treat breast cancer. Unfortunately there are very limited treatments for CIPN. This is a phase II randomized controlled trial to test the preliminary efficacy of exercise vs. nutrition education on CIPN, to systematically investigate the potential roles of inflammation and interoception, and to obtain data with a more accurate effect size to inform a future study.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

The Role of Nucleotide Excision Repair in Cisplatin-Induced Peripheral Neuropathy: Mechanism, Prevention, and Treatment.
Acklin S, Xia F. · · 2021 · cited 13× · PMID 33671279 · DOI 10.3390/ijms22041975
Pilot trial testing the effects of exercise on chemotherapy-induced peripheral neurotoxicity (CIPN) and the interoceptive brain system.
Kleckner IR, Manuweera T, Lin PJ, Chung KH, et al · · 2024 · cited 10× · PMID 39304604 · DOI 10.1007/s00520-024-08855-y
Preliminary evaluation of novel Bodily Attention Task to assess the role of the brain in chemotherapy-induced peripheral neurotoxicity (CIPN).
Manuweera T, Wagenknecht A, Kleckner AS, Dorsey SG, et al · · 2024 · cited 7× · PMID 38070689 · DOI 10.1016/j.bbr.2023.114803

Verify or expand the search:

Other trials of EXCAP Exercise

Trials testing the same drug.

NCT05452902 — Exercise and Nutrition Interventions for Platinum Chemotherapy-induced Neuropathy R21 · Phase 2 · terminated
NCT03021174 — Exercise and Nutrition Interventions During Chemotherapy · NA · completed

Other recruiting trials for Neuropathy;Peripheral

Currently open trials in the same condition.

NCT07427537 — Exploration of Circulating microRNAs as Biomarkers of Chemo-induced Peripheral Neuropathy: a Study in Cancer Patients · NA · recruiting
NCT06912646 — Clinical Efficacy of the Erchonia EVRL for Providing Temporary Relief of Idiopathic Peripheral Neuropathy Foot Pain · NA · recruiting
NCT06471517 — Neuroprosthetic Device for Improving Issues Caused by Diabetic Neuropathy With Specifically Designed Neural Stimulation · NA · recruiting
NCT05980169 — The Effect of Low Frequency Soundwave Stimulation on Chemotherapy Induced Peripheral Neuropathy · NA · active not recruiting
NCT06121232 — Exploring the Benefit of Neuromodulation in Treating Chemo-induced Peripheral Neuropathy Using Peripheral Neuropathy Mar · NA · active not recruiting

Other University of Rochester trials

Trials by the same sponsor.

NCT07075965 — Calcium Channel Blocker in Myotonic Dystrophy Type 1 · Phase 1 · not yet recruiting
NCT07423104 — A Study of Cladribine, Low Dose Cytarabine, and Venetoclax in Treatment of Relapsed/Refractory or Secondary Acute Myeloi · Phase 2 · not yet recruiting
NCT05744869 — SBAT for Health Equity · NA · not yet recruiting
NCT06052956 — Efficacy of Methylene Blue Photodynamic Therapy for Treatment of Deep Tissue Abscesses · Phase 2 · not yet recruiting
NCT07032636 — Reducing Crises and Suicide Within the Idaho Army National Guard · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03858153 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Rochester
Last refreshed: 22 December 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03858153.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing